Why the study?
Does bardoxolone methyl reduce the risk of ESRD or death from cardiovascular causes in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease?
Does bardoxolone methyl reduce the risk of ESRD or death from cardiovascular causes in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease?
Bardoxolone methyl does not improve renal or cardiovascular outcomes in patients with type 2 diabetes and stage 4 CKD, and is associated with an increased risk of cardiovascular events.
Answers are grounded in this paper and cite their sources.
Bardoxolone methyl should not be used in type 2 diabetes with stage 4 CKD; challenges prior signals of renal benefit.
Among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, bardoxolone methyl did not reduce the risk of ESRD or death from cardiovascular causes. A higher rate of cardiovascular events with bardoxolone methyl than with placebo prompted termination of the trial. (Funded by Reata Pharmaceuticals; BEACON ClinicalTrials.gov number, NCT01351675.).
No takes yet. Share an insight, caveat, or question.
Zeeuw et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: